Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWN NASDAQ:ELTX NASDAQ:GHRS NASDAQ:PVLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.95+7.0%$6.97$5.64▼$16.76$814.33M-1.261.19 million shs3.24 million shsELTXElicio Therapeutics$11.04-0.3%$0.00$0.00▼$0.00$180.37M1.1968,041 shs180,616 shsGHRSGH Research$13.10-1.8%$13.30$6.00▼$20.50$681.57M0.97293,571 shs528,064 shsPVLAPalvella Therapeutics$65.78+5.0%$51.46$11.17▼$65.80$727.53M-0.13181,002 shs151,211 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%+17.43%+7.29%+16.91%-41.63%ELTXElicio Therapeutics-0.27%+0.36%+6.56%+39.57%+123.48%GHRSGH Research0.00%-9.28%-6.76%-12.14%+107.28%PVLAPalvella Therapeutics0.00%+10.39%+21.50%+172.72%+6,577,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.95+7.0%$6.97$5.64▼$16.76$814.33M-1.261.19 million shs3.24 million shsELTXElicio Therapeutics$11.04-0.3%$0.00$0.00▼$0.00$180.37M1.1968,041 shs180,616 shsGHRSGH Research$13.10-1.8%$13.30$6.00▼$20.50$681.57M0.97293,571 shs528,064 shsPVLAPalvella Therapeutics$65.78+5.0%$51.46$11.17▼$65.80$727.53M-0.13181,002 shs151,211 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%+17.43%+7.29%+16.91%-41.63%ELTXElicio Therapeutics-0.27%+0.36%+6.56%+39.57%+123.48%GHRSGH Research0.00%-9.28%-6.76%-12.14%+107.28%PVLAPalvella Therapeutics0.00%+10.39%+21.50%+172.72%+6,577,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 2.89Moderate Buy$25.29218.06% UpsideELTXElicio Therapeutics 2.00Hold$13.0017.75% UpsideGHRSGH Research 2.67Moderate Buy$32.00144.27% UpsidePVLAPalvella Therapeutics 2.92Moderate Buy$69.275.31% UpsideCurrent Analyst Ratings BreakdownLatest ELTX, GHRS, DAWN, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/2/2025PVLAPalvella TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $80.009/27/2025DAWNDay One BiopharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ELTXElicio TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025GHRSGH ResearchWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PVLAPalvella TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/26/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $73.009/25/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $95.009/24/2025PVLAPalvella TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $80.009/9/2025PVLAPalvella TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$85.008/19/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $66.008/18/2025DAWNDay One BiopharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$131.16M6.21N/AN/A$4.99 per share1.59ELTXElicio Therapeutics$2.30M78.43N/AN/A($1.03) per share-10.72GHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/APVLAPalvella Therapeutics$42.81M16.99N/AN/A$5.58 per share11.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$95.50M-$0.95N/AN/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)ELTXElicio Therapeutics-$51.90M-$6.950.00N/AN/AN/AN/A-175.83%N/AGHRSGH Research-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%11/13/2025 (Estimated)PVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-62.30%-43.34%11/12/2025 (Estimated)Latest ELTX, GHRS, DAWN, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/29/2025Q3 2025DAWNDay One Biopharmaceuticals-$0.28N/AN/AN/A$38.20 millionN/A8/14/2025Q2 2025PVLAPalvella Therapeutics-$0.78-$0.86-$0.08-$0.86N/AN/A8/7/2025Q2 2025ELTXElicio Therapeutics-$0.69-$0.66+$0.03-$0.66N/AN/A8/7/2025Q2 2025GHRSGH Research-$0.22-$0.15+$0.07-$0.15N/AN/A8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AELTXElicio TherapeuticsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A9.659.53ELTXElicio Therapeutics5.092.282.28GHRSGH ResearchN/A29.4929.49PVLAPalvella TherapeuticsN/A7.677.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%ELTXElicio Therapeutics35.03%GHRSGH Research56.90%PVLAPalvella Therapeutics40.11%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals6.20%ELTXElicio Therapeutics50.90%GHRSGH Research41.60%PVLAPalvella Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60102.43 million96.08 millionOptionableELTXElicio TherapeuticsN/A16.34 million8.02 millionNot OptionableGHRSGH Research1052.03 million30.38 millionOptionablePVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/AELTX, GHRS, DAWN, and PVLA HeadlinesRecent News About These CompaniesStrid Group LLC Lowers Stake in Palvella Therapeutics, Inc. $PVLAOctober 5 at 5:21 AM | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Stock Price Expected to Rise, Truist Financial Analyst SaysOctober 4 at 2:21 AM | americanbankingnews.comPalvella Therapeutics price target raised to $80 from $56 at TruistOctober 2 at 4:21 PM | msn.comPalvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $80.00October 2 at 12:41 PM | marketbeat.comCritical Review: Palvella Therapeutics (NASDAQ:PVLA) and Bionano Genomics (NASDAQ:BNGO)October 2 at 3:51 AM | americanbankingnews.comPalvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High on Analyst UpgradeOctober 1, 2025 | americanbankingnews.comEquities Analysts Set Expectations for PVLA FY2028 EarningsSeptember 30, 2025 | americanbankingnews.comPalvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High After Analyst UpgradeSeptember 29, 2025 | marketbeat.comEquities Analysts Offer Predictions for PVLA FY2028 EarningsSeptember 29, 2025 | marketbeat.comChardan Capital Boosts Palvella Therapeutics (NASDAQ:PVLA) Price Target to $73.00September 28, 2025 | americanbankingnews.comChardan Capital Maintains Palvella Therapeutics (PVLA) Buy RecommendationSeptember 26, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $73.00 at Chardan CapitalSeptember 26, 2025 | marketbeat.comGoldman Sachs Group Inc. Makes New $533,000 Investment in Palvella Therapeutics, Inc. $PVLASeptember 26, 2025 | marketbeat.comHC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy RecommendationSeptember 26, 2025 | msn.comStifel Nicolaus Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) StockSeptember 26, 2025 | americanbankingnews.comPalvella Therapeutics price target raised to $95 from $75 at H.C. WainwrightSeptember 25, 2025 | msn.comPalvella Expands QTORIN Gel Program for Rare DiseaseSeptember 25, 2025 | msn.comPalvella Therapeutics expands QTORIN rapamycin development programSeptember 24, 2025 | msn.comPalvella Therapeutics price target raised to $80 from $60 at StifelSeptember 24, 2025 | msn.comStifel Nicolaus Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $80.00September 24, 2025 | marketbeat.comPalvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease ...September 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025NIO's New Dawn: Why Wall Street's Bullish Turn Signals a ComebackBy Jeffrey Neal Johnson | September 19, 2025ELTX, GHRS, DAWN, and PVLA Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWN$7.95 +0.52 (+7.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$8.02 +0.07 (+0.82%) As of 10/3/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Elicio Therapeutics NASDAQ:ELTXAngion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.GH Research NASDAQ:GHRS$13.10 -0.24 (-1.80%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$13.31 +0.21 (+1.60%) As of 10/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Palvella Therapeutics NASDAQ:PVLA$65.78 +3.15 (+5.03%) As of 10/3/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
